Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.07.007Source: DataRank Database

Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation is a research paper published in Transplantation and Cellular Therapy (2024). On theSindex it has a DataRank of 0.269. It has been cited 5 times.

N/A

0.269DataRank · unranked

Scored on demand from live citation data

5 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: closedTopics (30)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (11)

Svatava Merkle ORCID,Qing Cao ORCID,Rebecca Tryon ORCID,Gregory M. Vercellotti ORCID,Shernan G. Holtan ORCID

Live enrichment

PubMed:39002862

National Cancer Institute

Grant: P30CA077598

National Institutes of Health

closedLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

publisherhttps://api.elsevier.com/content/article/PII:S266663672400530X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S266663672400530X?httpAccept=text/plain

MeSH Terms

TelomereHumansBone Marrow DiseasesMyelodysplastic SyndromesDyskeratosis CongenitaGraft vs Host DiseaseCyclophosphamideVidarabineTransplantation ConditioningHematopoietic Stem Cell TransplantationTransplantation, HomologousProspective StudiesAdolescentAdultMiddle AgedChildChild, PreschoolInfantFemaleMaleYoung AdultAntibodies, Monoclonal, HumanizedAlemtuzumabBone Marrow Failure Disorders

Keywords

Dyskeratosis congenitaBone Marrow FailureReduced-intensity ConditioningTelomere Biology DisorderRadiation-sparingMyelodysplastic Disorder

Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation

FAIR Checklist

DataRank Breakdown

Authors (11)

Funding (2 grants)

Open Access

Topics